CRP and diabetes mellitus: In patients with diabetes, an 8-week treatment with dapagliflozin significantly increased the abundance of butyrate-producing bacteria (e.g., Butyricicoccus), along with reductions in C-reactive protein (CRP) and fecal LPS levels.